PROK
ProKidney
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 1
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About PROK
Prokidney Corp.
A US-based biotech company that develops and commercializes novel therapies for chronic kidney disease
Biological Technology
02/25/2021
06/30/2021
NASDAQ Stock Exchange
204
12-31
Common stock
2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, NC 27103
--
ProKidney Corp. is a new company incorporated under the laws of the Cayman Islands on February 25, 2021. The company is a pioneer in the innovative treatment of chronic kidney disease (CKD) through cell therapy. The company's lead product candidate, REACT (Renal Autologous Cell Therapy), is a first-of-its-kind patented disease-modifying autologous cell therapy that not only has the potential to slow and stabilize the progression of CKD, but also drives significant improvements in renal function in some cases.
Company Financials
EPS
PROK has released its 2024 Q4 earnings. EPS was reported at -0.16, versus the expected -0.15, missing expectations. The chart below visualizes how PROK has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PROK has released its 2024 Q4 earnings report, with revenue of 76.00K, reflecting a YoY change of NaN%, and net profit of -48.48M, showing a YoY change of -123.18%. The Sankey diagram below clearly presents PROK’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
